BELLANDO RANDONE, SILVIA
 Distribuzione geografica
Continente #
NA - Nord America 5.550
EU - Europa 3.878
AS - Asia 763
Continente sconosciuto - Info sul continente non disponibili 6
SA - Sud America 6
AF - Africa 5
OC - Oceania 2
Totale 10.210
Nazione #
US - Stati Uniti d'America 5.534
PL - Polonia 1.399
IT - Italia 989
IE - Irlanda 631
SE - Svezia 384
HK - Hong Kong 334
CN - Cina 165
JO - Giordania 84
GB - Regno Unito 82
FI - Finlandia 74
AT - Austria 66
DE - Germania 64
CH - Svizzera 56
IN - India 56
VN - Vietnam 52
SG - Singapore 39
ES - Italia 26
RU - Federazione Russa 26
UA - Ucraina 25
BE - Belgio 23
CA - Canada 15
TR - Turchia 14
NL - Olanda 8
FR - Francia 7
EU - Europa 6
JP - Giappone 5
KR - Corea 4
NO - Norvegia 3
RO - Romania 3
VE - Venezuela 3
AU - Australia 2
BA - Bosnia-Erzegovina 2
EG - Egitto 2
ID - Indonesia 2
IL - Israele 2
IR - Iran 2
LV - Lettonia 2
MK - Macedonia 2
MU - Mauritius 2
BO - Bolivia 1
CL - Cile 1
CO - Colombia 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
GE - Georgia 1
KZ - Kazakistan 1
LT - Lituania 1
MX - Messico 1
MY - Malesia 1
PT - Portogallo 1
RS - Serbia 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
Totale 10.210
Città #
Warsaw 1.398
Fairfield 966
Dublin 624
Ashburn 511
Chandler 496
Woodbridge 475
Seattle 392
Houston 357
Cambridge 356
Wilmington 300
Lawrence 210
Florence 196
Hong Kong 196
Altamura 194
Princeton 168
Ann Arbor 156
Boston 113
Beijing 105
San Diego 58
Rome 53
Boardman 51
Pune 50
Bern 47
Milan 46
Dong Ket 44
Buffalo 43
Medford 43
Vienna 40
Falls Church 39
Singapore 38
Shanghai 36
Norwalk 27
Moscow 23
Brussels 22
London 22
Jacksonville 21
Barcelona 20
Hillsboro 18
Andover 15
Naples 15
New York 15
Cagliari 14
Fiesole 13
Izmir 12
Toronto 12
Castelliri 11
Redwood City 11
Phoenix 10
Hanover 7
Moie 7
Bologna 6
Hefei 6
Cantagallo 5
Città della Pieve 5
Dearborn 5
Düsseldorf 5
Genoa 5
Nardò 5
Prato 5
Sesto Fiorentino 5
Arosio 4
Camerino 4
Chapel Hill 4
Chiswick 4
Chiusi 4
Messina 4
Padova 4
Reggio Emilia 4
Scandicci 4
Arezzo 3
Bari 3
Barquisimeto 3
Bonate Sotto 3
Brescia 3
Campi Bisenzio 3
Chicago 3
Cugnoli 3
Guangzhou 3
Guidonia Montecelio 3
Hamburg 3
Hounslow 3
Joppolo 3
Lucca 3
Oslo 3
Palermo 3
Pavia 3
Plesio 3
Salerno 3
Tappahannock 3
Washington 3
Acton 2
Adelfia 2
Altavilla Monferrato 2
Asyut 2
Atlanta 2
Bagnacavallo 2
Bergamo 2
Bremen 2
Bridgwater 2
Bucharest 2
Totale 8.267
Nome #
ENDOMETRIOSI E MALATTIE REUMATICHE: LA PUNTA DELL’ICEBERG DEI NUMEROSI DISTURBI MESTRUALI IN CORSO DI MALATTIA REUMATICA 261
Systemic Sclerosis Sera Impair Angiogenic Performance of Dermal Microvascular Endothelial Cells: Therapeutic Implications of Cyclophosphamide 237
Critical finger ischemia and myocardial fibrosis development after sudden interruption of sildenafil treatment in a systemic sclerosis patient. 231
Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis 220
Interstitial lung disease in systemic sclerosis: Where do we stand? 217
Angiogenic T cell expansion correlates with severity of peripheral vascular damage in systemic sclerosis 210
Very Early Diagnosis of Systemic Sclerosis (Diagnosi molto precoce della Sclerosi Sistemica) VEDOSS, 2010-2015 (2020). Validazione dei segni e sintomi in uno studio prospettico osservazionale di coorte 203
Decreased expression of the endothelial cell-derived factor EGFL7 in systemic sclerosis: potential contribution to impaired angiogenesis and vasculogenesis 194
Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population 180
Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis 169
The "myth" of loss of angiogenesis in systemic sclerosis: A pivotal early pathogenetic process or just a late unavoidable event? 161
Assessment, definition, and classification of lower limb ulcers in systemic sclerosis: A challenge for the rheumatologist 133
Proangiogenic effects of soluble α-Klotho on systemic sclerosis dermal microvascular endothelial cells 120
18F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis 118
Vascular leaking, a pivotal and early pathogenetic event in systemic sclerosis: should the door be closed? 116
Decreased expression of neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy and defective angiogenesis in systemic sclerosis 113
Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis 108
Agonistic anti-human Fas monoclonal antibody induces fibroblast-like synoviocyte apoptosis in haemophilic arthropathy: potential therapeutic implications 106
Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro 104
Digital ulcers predict a worse disease course in patients with systemic sclerosis 102
Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study 100
Decrease of LL-37 in systemic sclerosis: a new marker for interstitial lung disease? 99
Cardiac magnetic resonance predicts ventricular arrhythmias in scleroderma: the Scleroderma Arrhythmia Clinical Utility Study (SAnCtUS) 98
Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis 97
The Renal Resistive Index in systemic sclerosis: Determinants, prognostic implication and proposal for specific age-adjusted cut-offs 93
Calcinosis in systemic sclerosis: subsets, distribution and complications 91
A rare case of Candida glabrata spondylodiscitis: case report and literature review 90
Treatment options in systemic sclerosis 90
Angiostatic and Angiogenic Chemokines in Systemic Sclerosis: An Overview 90
The safety of iloprost in systemic sclerosis in a real-life experience 89
Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases 87
Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage 87
Systemic sclerosis and infections. 85
Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. 84
Increased circulating levels of interleukin-33 in systemic sclerosis correlate with early disease stage and microvascular involvement 79
Transitional connective tissue diseases: description of four cases 79
Enthesopathy and involvement of synovio-entheseal complex in systemic sclerosis: an ultrasound pilot study 79
Disease Activity Improvement in Rheumatoid Arthritis Treated with Tumor Necrosis Factor-α Inhibitors Correlates with Increased Soluble Fas Levels. 78
Implantable cardioverter defibrillator prevents sudden cardiac death in systemic sclerosis. 77
Clinical-Serological Characterization and Treatment Outcome of a Large Cohort of Italian Children with Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infection and Pediatric Acute Neuropsychiatric Syndrome 76
Preliminary Validation of the Digital Ulcer Clinical Assessment Score in Systemic Sclerosis. 76
Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis 75
Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis. 75
Pregnancy in systemic sclerosis (SSc): results of systematic review and meta-analysis 75
Immunosuppression for interstitial lung disease in systemic sclerosis. 73
From Raynaud's Phenomenon to Very Early Diagnosis of Systemic Sclerosis- The VEDOSS approach 73
Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis 73
Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre 73
The renal resistive index, a new biomarker for the follow up of vascular modifications in Systemic Sclerosis 72
Glycolysis-derived acidic microenvironment as a driver of endothelial dysfunction in systemic sclerosis 71
Increased plasma levels of the VEGF165b splice variant are associated with the severity of nailfold capillary loss in systemic sclerosis 70
Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies 70
"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. 70
Effects of rituximab in connective tissue disorders related interstitial lung disease 70
The role of the dermatologist in Raynaud's Phenomenon: a clinical challenge 69
Very early versus early disease: the evolving definition of the 'many faces' of systemic sclerosis. 69
Decreased circulating lymphatic endothelial progenitor cells in digital ulcer-complicated systemic sclerosis 69
Hydroxychloroquine and joint involvement in systemic sclerosis: Preliminary beneficial results from a retrospective case-control series of an EUSTAR center 68
Mixed Connective Tissue Disease, a Roundabout to Rheumatic Diseases? 68
Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis 68
Avascular bone necrosis: An underestimated complication of systemic sclerosis 68
Musculoskeletal involvement in systemic sclerosis. 66
Early detection of myocardial and pulmonary oedema with MRI in an asymptomatic systemic sclerosis patient: successful recovery with pulse steroid. 66
"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. 66
Antioxidant agents help primary Raynaud's phenomenon 64
Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: A randomized clinical trial 64
Pleuroparenchymal fibroelastosis in rheumatic autoimmune diseases: a systematic literature review 64
Bosentan fosters microvascular de-remodelling in systemic sclerosis. 62
GLI INTERVENTI INFERMIERISTICI RIVOLTI AI PAZIENTI AFFETTI DA MALATTIE REUMATICHE SOTTOPOSTI A TERAPIA CON FARMACI BIOLOGICI: REVISIONE SISTEMATICA DELLA LETTERATURA 61
Systemic Sclerosis Serum Significantly Impairs the Multi-Step Lymphangiogenic Process: in Vitro Evidence 61
Early Detection of Cardiac Involvement in Systemic Sclerosis: The Added Value of Magnetic Resonance Imaging 61
Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. 60
Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: a case report 59
"Atlas of Capilaroscopy in Rheumatic Diseases" - Chapter: The microcirculation and Rheumatic Diseases 59
Stiff Skin Syndrome 59
Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course 59
Sintomatologia gastrointestinale e qualità di vita dei pazienti affetti da Sclerosi Sistemica 57
Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis. 57
Very early diagnosis of systemic sclerosis. 57
Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement 55
THE CROSSTALK OF THE SKIN-ORAL-GUT MICROBIOME AXIS IN LIMITED AND DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS 55
Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors 54
The measurement of the endothelial glycocalyx as a new biomarker of endothelial derangement in systemic sclerosis: A challenge for the future 54
The Role of Endogenous Eicosapentaenoic Acid and Docosahexaenoic Acid-Derived Resolvins in Systemic Sclerosis 52
Decreased expression of the endothelial cell-derived factor EGFL7 contributes to impaired angiogenesis and vasculogenesis in systemic sclerosis 51
Patient subgroups and potential risk factors in systemic sclerosis: is there a possibility of an early diagnosis? 50
The positive side of the coin: Sars-Cov-2 pandemic has taught us how much Telemedicine is useful as standard of care procedure in real life 50
Implantable cardioverter defibrillator prevents sudden cardiac death in systemic sclerosis. 49
La riabilitazione multidisciplinare del malato reumatico 49
Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do? 49
Increased serum levels and tissue expression of MMP-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage 48
Very Early Systemic Sclerosis and Pre-systemic Sclerosis: Definition, Recognition, Clinical Relevance and Future Directions 48
Very early diagnosis of systemic sclerosis. 47
The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress 47
A candidate gene study reveals association between a variant of the SRp55 splicing factor gene and systemic sclerosis 46
The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19 45
Combination therapy with Bosentan and Sildenafil improves Raynaud’s phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis 45
COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series 45
Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: an in vitro study 42
A New Way of Thinking about Systemic Sclerosis: The Opportunity for a Very Early Diagnosis 42
Totale 8.671
Categoria #
all - tutte 32.231
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.231


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019722 0 0 0 0 0 0 0 0 38 140 297 247
2019/20201.982 134 134 37 142 236 234 231 239 216 144 207 28
2020/20211.663 117 101 104 309 81 136 98 122 159 259 99 78
2021/2022978 19 69 94 35 50 70 26 97 68 35 130 285
2022/20232.706 283 577 108 142 136 417 409 127 240 51 116 100
2023/20241.506 60 159 241 123 130 236 133 355 69 0 0 0
Totale 10.501